DEC-205 Double Nickase Plasmid (h): sc-417220-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DEC-205 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DEC-205 Double Nickase Plasmid (h) and DEC-205 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LY75. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DEC-205 Antibody (F-4): sc-515016
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DEC-205 Double Nickase Plasmid (h) | sc-417220-NIC | 20 µg | $410.00 | |||
DEC-205 Double Nickase Plasmid (h2) | sc-417220-NIC-2 | 20 µg | $410.00 |
LY75 encodes DEC-205 (CD205), a C-type lectin endocytic receptor highly expressed by dendritic cell subsets that captures glycosylated antigens and routes them to endosomal and lysosomal compartments for processing. Through clathrin-mediated uptake and vesicular trafficking, DEC-205 supports MHC class II presentation and can influence cross-presentation pathways that shape adaptive immune priming. DEC-205 engagement intersects with pattern-recognition and cytokine-driven programs that regulate dendritic cell maturation, tolerance, and T cell polarization. Dysregulated antigen handling and dendritic cell function involving LY75 are relevant to studies of autoimmunity, chronic inflammation, infection biology, and tumor immune microenvironments.
DEC-205 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LY75 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LY75. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LY75 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LY75-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.